Bevacizumab for Metastatic Colorectal Cancer with Chromosomal Instability: Cost-Effectiveness Analysis for a Novel Precision Treatment Approach in Germany, Ireland and Spain

Jonathan Briody, Ian S. Miller, James F. O’Mahony, Lesley Tilson, Alice C. O’Farrell, Qiushi Chen, Verena Murphy, Orla Casey, Nadine Schulte, Matthias P. Ebert, Jochen H. M. Prehn, Diether Lambrechts, Bauke Ylstra, Rodrigo Dienstmann, Annette T. Byrne, Kathleen Bennett

Open source

DOI: 10.1007/s40273-025-01585-x
Published: 2026-02-04
Container: PharmacoEconomics
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40273-025-01585-x,
  title = {Bevacizumab for Metastatic Colorectal Cancer with Chromosomal Instability: Cost-Effectiveness Analysis for a Novel Precision Treatment Approach in Germany, Ireland and Spain},
  author = {Jonathan Briody and Ian S. Miller and James F. O’Mahony and Lesley Tilson and Alice C. O’Farrell and Qiushi Chen and Verena Murphy and Orla Casey and Nadine Schulte and Matthias P. Ebert and Jochen H. M. Prehn and Diether Lambrechts and Bauke Ylstra and Rodrigo Dienstmann and Annette T. Byrne and Kathleen Bennett},
  year = {2026},
  journal = {PharmacoEconomics},
  doi = {10.1007/s40273-025-01585-x},
  url = {https://doi.org/10.1007/s40273-025-01585-x}
}

RIS

TY  - JOUR
TI  - Bevacizumab for Metastatic Colorectal Cancer with Chromosomal Instability: Cost-Effectiveness Analysis for a Novel Precision Treatment Approach in Germany, Ireland and Spain
AU  - Jonathan Briody
AU  - Ian S. Miller
AU  - James F. O’Mahony
AU  - Lesley Tilson
AU  - Alice C. O’Farrell
AU  - Qiushi Chen
AU  - Verena Murphy
AU  - Orla Casey
AU  - Nadine Schulte
AU  - Matthias P. Ebert
AU  - Jochen H. M. Prehn
AU  - Diether Lambrechts
AU  - Bauke Ylstra
AU  - Rodrigo Dienstmann
AU  - Annette T. Byrne
AU  - Kathleen Bennett
PY  - 2026
JO  - PharmacoEconomics
DO  - 10.1007/s40273-025-01585-x
UR  - https://doi.org/10.1007/s40273-025-01585-x
ER  -

APA

Briody, J., Miller, I. S., O’Mahony, J. F., Tilson, L., O’Farrell, A. C., Chen, Q., Murphy, V., Casey, O., Schulte, N., Ebert, M. P., Prehn, J. H. M., Lambrechts, D., Ylstra, B., Dienstmann, R., Byrne, A. T., & Bennett, K. (2026). Bevacizumab for Metastatic Colorectal Cancer with Chromosomal Instability: Cost-Effectiveness Analysis for a Novel Precision Treatment Approach in Germany, Ireland and Spain. PharmacoEconomics. https://doi.org/10.1007/s40273-025-01585-x

Source records

crossref · retrieved 2026-09-25T17:07:16.364Z